The effect of pregnancy vitamin D supplementation on maternal blood pressure: real-world data analysis within the MAVIDOS randomised placebo-controlled trial
The effect of pregnancy vitamin D supplementation on maternal blood pressure: real-world data analysis within the MAVIDOS randomised placebo-controlled trial
Purpose: observational studies have suggested negative associations between maternal 25-hydroxyvitamin D (25(OH)D) status and risk of hypertensive disorders of pregnancy [pregnancy-induced hypertension (PIH) and preeclampsia (PET)]. Data from intervention studies are limited. We hypothesised that vitamin D supplementation would lower maternal blood pressure (BP) during pregnancy and reduce the incidence of hypertensive disorders of pregnancy.
Methods: the Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a randomised placebo-controlled trial. Pregnant women with a baseline 25(OH)D of 25–100 nmol/l were randomized to either 1000 IU/day cholecalciferol or placebo from 14 to 17 weeks’ gestation until delivery. BP recordings documented during routine clinical pregnancy care were obtained from clinical records and grouped into gestational windows based on the schedule for routine antenatal care in the United Kingdom (23+0–24+6, 27+0–28+6, 33+0–35+6, 37+0–38+6, 39+0–40+6 and ≥ 41+0 weeks+days). Systolic and diastolic BP measurements in these gestational windows were compared between randomisation groups. Diagnoses of PIH or PET (in accordance with national guidelines) and the use of antihypertensive agents were also noted and compared between groups.
Results: data for 734 women (366 cholecalciferol, 368 placebo) were included. Maternal mean systolic and diastolic BP did not differ between the randomization groups at any of the gestations studied. The incidences of PIH (placebo 1.6%, cholecalciferol 3.6%, p = 0.10) and PET (placebo 3.3%, cholecalciferol 3.8%, p = 0.68) were similar between the two groups.
Conclusions: gestational vitamin D supplementation with 1000 IU/day from 14 to 17 weeks gestation did not lower maternal BP or reduce the incidences of PIH or PET in this trial.
Pregnancy-induced hypertension, Cholecalciferol, Preeclampsia, Hypertensive disorders of pregnancy
941-949
Citeroni, Natasha L.
fe42457c-fce7-469a-9c6d-538f12eadad6
D'angelo, Stefania
13375ecd-1117-4b6e-99c0-32239f52eed6
Crozier, Sarah R.
9c3595ce-45b0-44fa-8c4c-4c555e628a03
Kermack, Alexandra J
a5d1cbbf-3928-45dd-abc9-e5c394ea3fc9
Godfrey, Keith M.
0931701e-fe2c-44b5-8f0d-ec5c7477a6fd
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Moon, Rebecca J.
954fb3ed-9934-4649-886d-f65944985a6b
April 2025
Citeroni, Natasha L.
fe42457c-fce7-469a-9c6d-538f12eadad6
D'angelo, Stefania
13375ecd-1117-4b6e-99c0-32239f52eed6
Crozier, Sarah R.
9c3595ce-45b0-44fa-8c4c-4c555e628a03
Kermack, Alexandra J
a5d1cbbf-3928-45dd-abc9-e5c394ea3fc9
Godfrey, Keith M.
0931701e-fe2c-44b5-8f0d-ec5c7477a6fd
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Moon, Rebecca J.
954fb3ed-9934-4649-886d-f65944985a6b
Citeroni, Natasha L., D'angelo, Stefania, Crozier, Sarah R., Kermack, Alexandra J, Godfrey, Keith M., Cooper, Cyrus, Harvey, Nicholas C. and Moon, Rebecca J.
(2025)
The effect of pregnancy vitamin D supplementation on maternal blood pressure: real-world data analysis within the MAVIDOS randomised placebo-controlled trial.
Archives of Gynecology and Obstetrics, 311 (4), , [b2255].
(doi:10.1007/s00404-025-07958-z).
Abstract
Purpose: observational studies have suggested negative associations between maternal 25-hydroxyvitamin D (25(OH)D) status and risk of hypertensive disorders of pregnancy [pregnancy-induced hypertension (PIH) and preeclampsia (PET)]. Data from intervention studies are limited. We hypothesised that vitamin D supplementation would lower maternal blood pressure (BP) during pregnancy and reduce the incidence of hypertensive disorders of pregnancy.
Methods: the Maternal Vitamin D Osteoporosis Study (MAVIDOS) was a randomised placebo-controlled trial. Pregnant women with a baseline 25(OH)D of 25–100 nmol/l were randomized to either 1000 IU/day cholecalciferol or placebo from 14 to 17 weeks’ gestation until delivery. BP recordings documented during routine clinical pregnancy care were obtained from clinical records and grouped into gestational windows based on the schedule for routine antenatal care in the United Kingdom (23+0–24+6, 27+0–28+6, 33+0–35+6, 37+0–38+6, 39+0–40+6 and ≥ 41+0 weeks+days). Systolic and diastolic BP measurements in these gestational windows were compared between randomisation groups. Diagnoses of PIH or PET (in accordance with national guidelines) and the use of antihypertensive agents were also noted and compared between groups.
Results: data for 734 women (366 cholecalciferol, 368 placebo) were included. Maternal mean systolic and diastolic BP did not differ between the randomization groups at any of the gestations studied. The incidences of PIH (placebo 1.6%, cholecalciferol 3.6%, p = 0.10) and PET (placebo 3.3%, cholecalciferol 3.8%, p = 0.68) were similar between the two groups.
Conclusions: gestational vitamin D supplementation with 1000 IU/day from 14 to 17 weeks gestation did not lower maternal BP or reduce the incidences of PIH or PET in this trial.
Text
MAVIDOS BP Revision January 2025 - no tracked changes
- Accepted Manuscript
Text
s00404-025-07958-z (1)
- Version of Record
More information
Accepted/In Press date: 12 January 2025
e-pub ahead of print date: 30 January 2025
Published date: April 2025
Additional Information:
For the purpose of Open Access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.
Keywords:
Pregnancy-induced hypertension, Cholecalciferol, Preeclampsia, Hypertensive disorders of pregnancy
Identifiers
Local EPrints ID: 498276
URI: http://eprints.soton.ac.uk/id/eprint/498276
ISSN: 0932-0067
PURE UUID: 8be0f9e8-1779-4b6f-b2c5-1ee1e7b43914
Catalogue record
Date deposited: 13 Feb 2025 17:45
Last modified: 22 Aug 2025 02:07
Export record
Altmetrics
Contributors
Author:
Natasha L. Citeroni
Author:
Stefania D'angelo
Author:
Alexandra J Kermack
Author:
Rebecca J. Moon
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics